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Abstract
In HIV-1 infected cells transcription of the integrated provirus generates the single full length 9 kb
viral RNA, a major fraction of which is spliced to produce the single-spliced 4 kb RNAs and the
multiple-spliced 2 kb RNAs. These spliced RNAs are the messengers for the Env glycoproteins and
the viral regulatory factors. The cellular SR and hnRNP proteins were shown in vitro to control
alternative splicing by binding cis-regulatory elements on the viral RNA. To better understand in
vivo the role of the SR proteins on HIV-1 genomic RNA splicing and virion production, we used a
human cell line expressing high levels of complete HIV-1 and either one of the ASF/SF2, SC35, and
9G8 SR proteins. Results show that over-expressing SR proteins caused a large reduction of
genomic RNA and that each SR protein modified the viral 9 kb RNA splicing pattern in a specific
mode. In fact, ASF/SF2 increased the level of Vpr RNA while SC35 and 9G8 caused a large increase
in Tat RNA. As expected, overexpressing SR proteins caused a strong reduction of total Gag made.
However, we observed by immuno-confocal microscopy an accumulation of Gag at the plasma
membrane and in intracellular compartments while there is a dramatic reduction of Env protein
made in most cells. Due to the negative impact of the SR proteins on the levels of genomic RNA
and HIV-1 structural proteins much less virions were produced which retained part of their
infectivity. In conclusion, SR proteins can down-regulate the late steps of HIV-1 replication.
Background
From a genome of only 9000 nt in length, HIV-1 directs
the synthesis of 15 proteins essential for its replication
and dissemination (for review see ref. [1]). In order to
generate mRNAs required for the synthesis of these pro-
teins, HIV-1 uses the cellular splicing machinery. Through
alternative splicing of its primary RNA transcript contain-
ing 4 donor sites (D1, D2, D3 and D4) and 8 acceptor
sites (A1, A2, A3, A4a, A4b, A4c, A5 and A7), more than
30 different mRNAs are generated and divided into three
classes of 2 kb, 4 kb and 9 kb in length (Figure 1) [2]. The
2 kb mRNAs are fully spliced and principally encode the
regulatory proteins Tat and Rev and accessory proteins
Nef and Vpr. The single-spliced 4 kb RNAs are bicistronic
and code for the Env glycoproteins and viral factor Vpu,
and the unspliced 9 kb RNA serves both as mRNAs for the
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HIV-1 splicing pattern Figure 1
HIV-1 splicing pattern. Schematic representation of HIV-1 proviral DNA. Open boxes represent the open reading frames 
encoding the viral proteins. Black boxes represent exons generated by combination of donor sites (D1 to D4) and acceptor 
sites (A1 to A7). The viral translation initiator codons are indicated by AUG.
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Gag and Gag-Pol polyproteins as well as pre-genomic
RNA for Gag assembly. Rev is crucial because it directs the
export of the unspliced and single-spliced mRNAs from
the nucleus to the cytoplasm that permits their translation
[3,4]. A fine tuning of splicing is then critical to ensure the
balance between spliced versus unspliced viral RNAs.
HIV-1 splicing regulation relies on the presence of (i) sub-
optimal splice sites [5,6], (ii) exonic and intronic cis-act-
ing elements [7-15] and (iii) trans-acting factors (generally
hnRNPs and SR proteins) that mediate their effects by
binding these elements [16-19]. SR proteins belong to a
conserved family of structurally and functionally related
phosphoproteins (for review, ref. [20]). These proteins
participate in constitutive splicing by causing stabilizing
interactions with components of the splicing machinery
and are able to influence the choice of splicing sites in
alternative splicing (for review see ref. [20]). The high
level of conservation of the splicing pattern in different
HIV expressing cells suggests that splicing regulation is
critical for efficient virus replication [2,21,22]. Because SR
proteins ASF/SF2, SC35, 9G8 and SRp40 have been
shown to cause an imbalance in the HIV-1 splicing pattern
in vitro and ex vivo [19,23-26], we investigated the impact
of SR protein over-expression on virus production and
infectivity in a human cell line expressing infectious HIV-
1.
In the present study we show that overexpression of one
of the three SR proteins ASF/SF2, SC35 and 9G8 together
with HIV-1 strongly affected the full length viral RNA
splicing pattern, notably resulting in a strong reduction of
the genomic RNA and Env mRNA levels. As a conse-
quence, only small amounts of viral particles were pro-
duced which, however, retained part of their infectivity.
Results
SR proteins alter the splicing pattern of HIV-1
Human cells (293T) were co-transfected by the calcium
phosphate precipitation method with 10 µg of HIV-1
pNL4-3 [27] and 10 µg of irrelevant plasmid pCLacZ
(control) or 5–10 µg of one of the SR protein-expression
vectors, pXJ41-ASF, pXJ42-PR264 and pXJ42-9G8, encod-
ing respectively ASF/SF2, SC35 and 9G8 proteins [26,28].
Expression of HIV-1 and SR proteins in co-transfected
cells was verified by immunoblotting assays (data not
shown). We first performed RT-PCR in conditions previ-
ously described [2,29] to verify that SR proteins modified
HIV-1 splicing pattern as reported elsewhere [26]. Multi-
ple-spliced 2 kb mRNAs isolated from ASF/SF2 over-
expressing cells showed that Vpr1, Tat2 and Tat3 were
strongly increased as compared with the control (Figures
1, 2A). These observations were confirmed by the analysis
of the 4 kb mRNAs where Tat6 and Vpr3 mRNAs became
the most represented in these conditions probably at the
expense of the Env mRNA which proved to accumulate at
a low level (Figure 2B). SC35 and 9G8 overexpression led
to similar splicing patterns where Tat1 and Tat5 mRNAs
were the most abundant spliced isoforms (Figures 1, 2). In
the case of SC35, splicing was almost completely driven
towards Tat1 production. Because Tat2 and Tat6 required
splicing at site A1 and Vpr1, Vpr3 and Tat3 mRNAs at site
A2, we concluded that ASF/SF2 participated in a positive
regulation of splicing at sites A1 and A2, while SC35 and
9G8 preferentially enhanced splicing at site A3 necessary
for Tat mRNA synthesis (Figure 1). These results are in
agreement with those obtained in HeLa cells using a trun-
cated non-infectious HIV-1 DNA construct [26] and
showed that SR proteins profoundly changed the HIV-1
splicing pattern. However the effects observed in the
present experimental conditions were stronger than with
the incomplete HIV-1 DNA construct [26].
To further study the SR-mediated commitment of the full
length viral RNA to splicing, that is increasing the ratio of
viral spliced versus  unspliced RNAs, we purified total
RNAs from cells expressing HIV-1 and either one of the SR
proteins and subjected 10 µg total RNA to Northern blot
analysis with an HIV-1 env-specific probe. In control HIV-
1 cells, 8 % of HIV-1 RNA remained unspliced while this
amount was lowered to 0.5% by ASF/SF2 and SC35, and
to 1.5% by 9G8. This also caused a decrease of total intra-
cellular viral RNAs by two to five fold (Table 1A). We con-
cluded that SR proteins are general activators of HIV-1
splicing, negatively regulating the steady state level of full
length viral RNA.
Alterations of HIV-1 splicing pattern by SR proteins modify 
viral protein synthesis
The profound modifications of the HIV-1 splicing pattern
by overexpression of one of the SR proteins were expected
to strongly influence viral protein synthesis. Since the
unspliced viral RNA serves both as the mRNA for Gag and
Gag-Pol synthesis and as the pregenome, we expected the
levels of Gag and newly made virions to be strongly
reduced by the SR proteins. To this end, levels of intracel-
lular HIV Gag were assessed by CAp24 ELISA on cell
lysates 48 h after DNA transfection (see methods). To
measure the levels of virion production, culture superna-
tants were harvested every day for two days, pooled, clari-
fied by filtration and ultracentrifuged through a 20 %
sucrose cushion. Pelleted viral particles were resuspended
in TNE buffer (see methods) and virus production was
monitored by CAp24 ELISA. Series of measurements indi-
cated that ASF/SF2 and SC35 caused about a 10–12 fold
reduction of total Gag synthesized while 9G8 reduced it
by roughly 4 fold. These results are in agreement with the
relative levels of the unspliced viral RNA in HIV-1 pro-
ducer cells (Table 1A).Retrovirology 2005, 2:33 http://www.retrovirology.com/content/2/1/33
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Regulation of HIV-1 alternative splicing by SR proteins Figure 2
Regulation of HIV-1 alternative splicing by SR proteins. Analysis of 2 kb (A) and 4 kb (B) mRNAs was performed by 
RT-PCR using 10 µg of total cellular RNA extracted from 293T cells transfected by HIV-1 pNL4.3 only (lane 1) or together 
with one SR plasmid (lanes 2–4). Viral mRNAs were identified according to the nomenclature of Purcell and Martin [2].
Table 1: Relative levels of the three viral mRNA classes. The amounts of radioactivy in mRNA signals identified by Northern blotting 
or by slot blotting experiments (see methods) were measured using a Storm scanner. (A) Relative levels of total intracellular viral 
RNA were determined as the sum of the radioactivity in the 3 signals corresponding to the 2, 4 and 9 kb mRNAs from the same 
experiments. Levels are expressed as the percentages of total viral RNA in cells transfected with HIV pNL4.3 only used as a reference 
(100 %) or with HIV-1 pNL4.3 and an SR plasmid. For the same degree of DNA transfection, the percentages of the unspliced and 
spliced mRNAs were calculated relative to the total viral RNA considered as 100 %. (B) Values of genomic RNA packaged into a 
standardized amounts of virions (CAp24 ELISA) are reported relative to the virions produced in the absence of SR protein 
overexpression (100%).
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Next we evaluated the relative amounts of cell-associated
versus virion-associated Gag. Despite the low levels of total
Gag synthesized as measured by CAp24 ELISA, cell-associ-
ated Gag was found at unexpected high levels when either
one of the SR proteins was overexpressed. Indeed, cell-
associated Gag levels were found to be about 40%, 80%
and even 250% upon overexpressing ASF, SC35 and 9G8,
respectively, as compared with control HIV-1 cells (Figure
3A). Pol was expressed as evidenced by Gag processing
and the presence of reverse transcriptase (RT) in the newly
formed infectious virions (see below). The pattern of Gag
processing by the viral protease was only slightly influ-
enced by overexpressing one of the SR proteins (Figure 3B,
compare lanes 2–4 to 1, upper panel).
A large fraction of the 4 kb mRNAs codes for Env. The very
low level of Env glycoproteins present in cells is consistent
with the fact that SR proteins strongly reduced the encod-
ing viral mRNA (Figure 2B; Figure 3B bottom panel).
Last we analysed viral protein synthesis directed by the
multiple spliced 2 kb mRNAs, coding for the regulatory
proteins Nef and Vpr and the trans-acting factors Tat and
Rev. Only the expression of Vpr was found to be markedly
enhanced by ASF/SF2 in agreement with the increased
level of Vpr mRNAs (Figure 2; Figure 3B, compare lanes 1
and 2; and data not shown).
Thus we can conclude that the SR proteins have a strong
indirect impact on viral protein synthesis due to their
alterations of the HIV-1 splicing pattern. Only the rather
high level of cell-associated Gag appears to contradict this
view (see discussion).
Influence of the SR proteins on Gag and Env expression 
analysed by immuno-confocal microscopy
To better understand the influence of the SR proteins on
Gag and Env synthesis, we examined by immunofluores-
cence staining and confocal laser microscopy (CLSM), co-
expression of the two major viral structural proteins in
individual cells. HIV-1 expressing cells were subjected to
immuno-staining using anti-MA for Gag (green staining)
and anti-gp120 for Env (red staining) antibodies, and all
stainings were viewed by confocal microscopy (Figure 4A)
(see methods). It is noteworthy that most, if not all, cells
co-expressed Gag and Env which accumulated at the
plasma membrane and in intracellular vesicles (merge
picture in Figure 4A). Co-expression of HIV-1 Gag and
Env was confirmed by examining 100 cells where Gag
only cells were hardly found, as expected with complete
HIV-1 (Figure 5).
Overexpressing ASF/SF2 as evidenced by a blue nuclear
staining in most cells (Figure 4B) caused a drastic
reduction of Env but only moderately affected Gag (Figure
4B, green and red stainings) in agreement with the west-
ern blot data (Figure 3B, lane 2). As above, Gag was seen
to accumulate in intracellular vesicles and at the plasma
membrane while Env was expressed in a heterogeneous
manner and mainly located in the cell interior (Figure 4B,
HIV Env panel), probably in the Golgi area and in intrac-
ellular vesicles (Figure 4B, merge picture). Quantitative
values on 100 cells, taking into account that 70–75% of
the cells were positively transfected, showed that co-
expression of Gag and ASF was observed in 25% of the
cells while Gag, Env and ASF was seen in only 10% of the
cells. At the same time 65% of the cells expressed ASF only
(Figure 5, bars labelled ASF). These results further showed
that the ASF/SF2 SR protein can have a drastic negative
impact on HIV-1 since its overexpression caused a nearly
complete suppression of Gag and Env expression in a
large fraction of the cells (Figures 4B &5). SC35 (Figure
4C) and 9G8 (not shown) SR proteins had less pro-
nounced effects since a majority of the cells coexpressed
Gag and one SR protein (Figure 5; 45 to 55 % see bars
labelled gag+SC35 and gag+9G8, respectively) or evenly
in the case of Gag, Env and 9G8 (Figure 5; see bar labelled
gag+env+9G8). These observations suggest that the SR
proteins can have differential effects on HIV-1 structural
protein expression.
The influence of the SR proteins on Gag and Env synthesis
was further evaluated with respect to virion production
and infectivity.
Influence of SR proteins on virion production and 
infectivity
This was examined by monitoring the levels of HIV-1 vir-
ion production under conditions of increasing expression
of the SR proteins. As shown in Figure 6A, SR proteins
overexpression induced a dose-dependent inhibition of
virion production as compared with control cells co-trans-
fected with HIV-1 pNL4.3 and an irrelevant expression
vector. A high dose of SR DNA, notably ASF/SF2, caused a
nearly complete inhibition of virion production.
Protein composition of the virions generated by cells
overexpressing one of the SR factors, at a HIV-1/SR DNA
ratio of 1:0.5, was investigated by western blotting using
antibodies against the major core component, CAp24, the
RT enzyme, viral factor VPR and the envelope glycopro-
tein TMgp41. As shown in Figure 6B, CAp24 and RT were
found as processed Gag protein and Pol enzyme, respec-
tively, in proportions similar or close to wt HIV-1 particles
(see panels labelled α CAp24 and α RT). On the contrary,
VPR was more abundant in virions upon overexpression
of ASF/SF2 in agreement with higher levels of the corre-
sponding viral mRNA and protein in cells (Figures 2 and
3B lane 2). With SC35 and 9G8 Vpr was hardly detected
in virions in agreement with the very low level of VprRetrovirology 2005, 2:33 http://www.retrovirology.com/content/2/1/33
Page 6 of 13
(page number not for citation purposes)
Influence of SR proteins on HIV-1 protein synthesis Figure 3
Influence of SR proteins on HIV-1 protein synthesis. 293T cells (2 × 105 per well) were transfected with 1 µg of HIV-1 
pNL4.3 in the presence of increasing amounts of plasmid encoding either ASF/SF2, SC35 or 9G8. DNA concentrations were 
maintained constant by supplementation with the pCLacZ control plasmid which also served to monitor transfection efficiency. 
Values reported here correspond to assays carried out with a HIV to SR DNA molar ratio of 1:05. Cells were recovered two 
days after DNA transfection. A: Levels of Gag production were assessed by CAp24 antigen ELISA and expressed as pg of CA 
per µg of total cellular proteins. Note that ASF had a clear negative impact on Gag accumulation in cells whereas 9G8 had an 
opposite effect. B: Equivalent amounts of CAp24 antigen as measured by ELISA were subjected to western blotting. The same 
membrane was alternatively probed with the respective antibodies as indicated on the right: anti-CAp24 for Gag, anti-Vpr for 
p15, anti-NEF for p27 and anti-TMgp41 for Env. The viral Gag, Vpr, NEF and Env proteins are indicated according to their 
molecular weights in kDaltons. Note that SR proteins did not change the Gag processing pattern (compare lanes 2–4 and 1). 
ASF caused an indirect increase of Vpr cellular accumulation (lane 2) in agreement with its positive effect on Vpr mRNA level 
(Figure 1). On the other hand SC35 and 9G8 had an opposite effect (lanes 3–4). All Env levels were low (lanes 2–4) except in 
the control (lane 1).
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mRNA and protein in cells (Figure 3B lanes 3–4). All SR
proteins examined negatively impacted on the incorpora-
tion of Env TMgp41 in virions (Figure 6B, lanes 2–4),
again in agreement with the fact that Env mRNA and
protein levels were drastically reduced in cells (Figures 2
and 3B).
To test whether the decreased level of cellular unspliced
viral RNA also caused an attenuation of genome packag-
ing into newly made virions, viral particles corresponding
to the same amounts of CAp24 were used to purify the
genomic RNA which was analyzed by slot-blotting using a
Confocal microscopy of cells co-expressing HIV-1 Gag, Env and SR-protein Figure 4
Confocal microscopy of cells co-expressing HIV-1 Gag, Env and SR-protein. Panel A: 293T cells expressing HIV-1 
pNL4.3 were subjected to immuno-staining using anti-Map17 (green staining) and anti-Env gp120 (red staining) antibodies and 
staining was viewed by confocal microscopy as described in methods. Most if not all cells expressed Gag and Env but only par-
tial colocalization was seen (merge picture). Right panel corresponds to the same cells viewed by phase contrast microscopy. 
Panel B: same as in A except that His tagged-ASF/SF2 SR protein was overexpressed by DNA transfection with about 75% 
transfection efficiency (see methods). ASF/SF2 protein is localized in the nucleus (blue staining) and its overexpression caused a 
drastic reduction of Env level while Gag remained well expressed in agreement with the western blot data (Figure 3) but with 
an heterogenous pattern (first panel). Panel C: same as in A except that His tagged-SC35 SR protein was overexpressed by 
DNA transfection with about 75% transfection efficiency (see methods). SC35 protein (nuclear blue staining) overexpression 
caused a reduction of Env level while Gag was still highly expressed in agreement with the western blot data (Figure 2). Note 
that in all cases examined here (anti-Map17; green staining in panel A to C) Gag was found to accumulate at the plasma mem-
brane and in intracellular compartments corresponding to vesicles [42] (Muriaux et al., unpublished data).
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gag-specific probe. For all overexpressed SR proteins,
genomic RNA packaging was reduced from 3 to 4 fold
compared with control virions (Table 1B).
To determine the infectivity of virions produced by cells
overexpressing one of the SR proteins, the same amount
of virus-associated genomic RNA was used to infect Hela
P4 cells, a HeLa subtype that constitutively expresses the
CD4 receptor and contains the lacZ gene under the con-
trol of the HIV-1 LTR. One day later, blue cells were
counted allowing us to assess virus infectivity (see meth-
ods). Upon overexpression of each one of the SR proteins,
virus infectivity, based on the same amount of genomic
RNA, was found to be 30 to 60% of the control virus, or 6
to 12 fold less based on identical amounts of CAp24-asso-
ciated particles.
It can be concluded that overexpression of each one of the
SR proteins caused a strong reduction of the unspliced
viral RNA in cells, and this had a more pronounced effet
on virion production than on Gag synthesis (Figures 2, 3,
4, 5, 6). At the same time levels of genomic RNA packaged
into progeny virions remained high (Table 1). These find-
ings are in full agreement with the fact that the genomic
RNA is considered to be an indispensable partner of Gag
in the course of virus assembly.
Influence of SR protein on cellular levels of HIV-1 Gag and Env Figure 5
Influence of SR protein on cellular levels of HIV-1 Gag and Env. 293T cells expressing HIV-1 and one SR protein 
(either ASF, SC35 or 9G8) were immuno-stained, examined and counted using Confocal Laser Scanning Microscopy (see figure 
4). Numbers are representative of more than 100 SR positive cells. For all experiments we evaluated the expression of Gag 
and Env, and SR protein when applicable. The numbers are expressed as the percentage of all SR positive cells given a DNA 
transfection efficiency of 70–75% (not shown). When HIV-1 pNL4.3 was transfected alone, 100% of the cells were found to co-
express Gag and Env (first bar). Upon co-transfection with the ASF coding DNA, a majority of the cells only expressed ASF and 
about half of them expressed Gag and the SR protein (see ASF bars). Upon co-transfection of pNL4.3 and either the SC35 or 
9G8 coding plasmid, a majority of cells expressed Gag and the SR protein (see SC35 and 9G8 bars).
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Discussion
In the present study, we show that the overexpression of
either one of three different SR proteins, namely ASF/SF2,
SC35 and 9G8, profoundly affected the HIV-1 splicing
pattern (Figure 1) [26], resulting in a drastic decrease of
virus production. However, the progeny virions still made
retained part of their infectivity. SR protein
overexpression caused an oversplicing of the HIV-1 full
length transcript and confirm that the targets of activation
depend on the SR protein overexpressed. Indeed, ASF/SF2
Expression of viral proteins results from alterations of splicing pattern Figure 6
Expression of viral proteins results from alterations of splicing pattern. 293T cells (2 × 105 per well) were trans-
fected with 1 µg of HIV-1 pNL4.3 in the presence of increasing amounts of plasmid encoding either ASF/SF2, SC35 or 9G8 
(ratios indicate molar amounts of HIV-1 DNA vs SR-expressing vector). DNA concentrations were maintained constant by 
supplementation with the pCLacZ control plasmid which also served to monitor transfection efficiency. A: Viral production 
was monitored by CAp24 antigen ELISA and expressed as ng of p24 per ml of medium (see methods). Results are representa-
tive of 3 independent experiments. Note that the effect of ASF/SF2 on virion production was already drastic at a HIV/SR molar 
ratio of 1:0.5. B: The pelleted viral particles were tested for their content in Gag, Pol, Env and Vpr proteins. Equivalent amounts 
of CAp24 antigen measured by ELISA were subjected to Western blotting. The same membrane was alternatively probed with 
the respective antibodies as indicated on the right: anti-CAp24 for Gag, anti-RT for p66 and p51, anti-Vpr for p15 and anti-
TMgp41 for Env. The viral Gag, RT, Vpr and Env proteins are indicated according to their molecular weights in kDaltons. Note 
that fully mature CAp24 and RTp66/p51 were abundant in all virion preparations. ASF caused an indirect increase of Vpr incor-
poration in virions (lane 2) whereas SC35 and 9G8 had an opposite effect (lanes 3–4). All Env levels were low (lanes 2–4) 
except in the control (lane 1).
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stimulates splicing at sites A1 and A2, while SC35 and
9G8 preferentially enhance splicing at site A3 (Figures 1,
2). In addition to being general activators of constitutive
splicing, results reported here confirm that each one of the
three SR proteins exerts specific effects on the alternative
splicing of HIV-1 primary RNA transcript (Figure 2) [26].
Little is known about the HIV-1 A1 site. Here, we show
that ASF/SF2 participates in the utilization of A1 by a
mechanism that requires further investigations. Many
elements act in concert to repress splicing at site A2 such
as its intrinsic weakness [5,6] and the existence of the
hnRNP A/B dependent ESSV located in the noncoding
exon flanking sites A2 and D3 [8,9]. Then how does ASF/
SF2 exert this control ? The exon bridging hypothesis pro-
poses that U1 snRNP binding to the downstream donor
site acts to increase splicing efficiency at the upstream
flanking acceptor site (for review see [20]). Also, SR pro-
teins are known to stabilize U1 snRNP binding on subop-
timal donor sites. Consequently, one can imagine that
ASF/SF2 reinforces splicing at site A2 by stabilizing spli-
ceosomal interactions at the suboptimal site D3. Accord-
ingly, other SR proteins like SC35 or 9G8 would be
expected to have the same effect as ASF/SF2 on site A2 and
thus on Vpr mRNA synthesis. This prediction is
inconsistent with our data (Figure 3) since overexpression
of SC35 and 9G8 did not increase Vpr RNA level. Another
possibility is that ASF/SF2 positively regulates splicing at
site A2 by counteracting the effect of ESSV. ESSV represses
splicing at site A2 by binding cellular hnRNP A/B proteins
[8,9]. This binding prevents the assembly of U2AF on the
polypyrimidine tract (PPT) and subsequently the
formation of a functional spliceosome between sites D1
and A2 [9]. SR proteins are thought to also activate weak
acceptor sites by facilitating the recruitment of U2AF on
the PPT [20]. It is tempting to speculate that the ratio
between hnRNP A/B and ASF/SF2 bound close to site A2
modulates the binding of U2AF at this site. This effect of
SR proteins is generally mediated by a splicing enhancer,
but whether an ASF/SF2-dependent splicing element is
required here remains to be determined.
Site A3 is used to generate Tat mRNAs. Like A2, A3 is
intrinsikly weak and repressed by hnRNP A/B-dependent
ESS2 and hnRNP H-dependent ESS2p [17,29]. Our results
show that a strong positive control is exerted by SR pro-
teins SC35 and 9G8 at this level. Findings on SC35 are
consistent with the recent data of Zahler et al. [19] report-
ing a novel ESE downstream of A3 that reinforces A3 uti-
lization in the presence of a high level of SC35 in vitro. In
addition, hnRNPs act in a trans-dominant manner to
counteract that of SC35 in vitro [19]. Taken together these
results strongly suggest that changing the hnRNP/SC35
ratio probably leads to activation or repression of splicing
at site A3. Little is known on the implications of SR pro-
tein 9G8 in HIV-1 splicing. The present data show that
9G8 appears to function in a way similar to SC35 (Figure
2). As for ASF/SF2, the exon bridging hypothesis can be
mentioned but 9G8 acts mainly by binding specific cis-
acting RNA elements [30]. Even if overexpression of SC35
and 9G8 caused a large accumulation of Tat mRNAs, it is
likely that these two SR proteins act by distinct mecha-
nisms. Indeed, firstly SELEX experiments showed that
9G8 and SC35 recognize different consensus RNA
sequences [30]. Secondly, ESS2 mutations that in vitro
strongly reinforce the binding of SC35 on an ESS2-con-
taining transcript have no effect on 9G8 binding to the
same substrate [19,30]. Sequences important for 9G8
splicing activation remain to be determined.
In conclusion, the exact molecular mechanisms by which
high levels of SR proteins cause a strong enhancement of
genomic RNA splicing and consequently a severe inhibi-
tion of HIV-1 virion production remain to be determined.
This is presently under investigation.
As expected, the profound changes of the HIV-1 splicing
pattern caused by the overexpression of one of the SR pro-
teins ASF/SF2, SC35 or 9G8 inhibited viral protein synthe-
sis, notably that of the structural proteins Gag and Env
(Figures 3, 4, 5) and consequently, virion production (Fig-
ure 6A). Still in agreement with such alterations of the
HIV-1 splicing pattern (Figures 1, 2), Vpr synthesis was
upregulated by ASF whereas SC35 and 9G8 had an oppo-
site effect (Figure 3B). But it was surprising to find a rather
high heterogeneous level of cell-associated Gag (Figure
3A). To explain this apparent discrepancy, one should
remember that the unspliced viral RNA performs two
essential functions, firstly as the mRNA for Gag and Gag-
Pol synthesis and secondly as the pregenome for Gag
assembly (reviewed in ref. [31]). In fact, the Gag assembly
process requires two platforms that are the genomic RNA
through specific NC-genomic RNA interactions [31,32]
and a cellular membrane in which Gag is anchored via
MA-membrane interactions (reviewed in ref. [33]). Mem-
branes are not limiting whereas the full length RNA is
probably limiting due to its mobilization by the translat-
ing ribosomes (reviewed in ref. [34]). Actually, the fate of
the full length viral RNA appears to result from a subtle
balance between Gag translation on ribosomes and core
assembly governed by Gag-genomic RNA interactions
(reviewed in refs [31,35]). In the presence of high
amounts of the SR proteins, the unspliced viral RNA is
even more limiting and thus probably rarely available for
assembly. Hence, the cell-associated Gag corresponds to
newly made free Gag molecules as well as Gag in newly
assembled core nucleocomplexes which accumulate in
the cell (Figure 4) before being released. According to this
scheme of virus assembly, the low levels of the prege-
nomic RNA (Table 1A) and Env (Figure 3B) upon SR over-Retrovirology 2005, 2:33 http://www.retrovirology.com/content/2/1/33
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expression may very well explain why Gag assembly and
virion release are most probably slowed down (Figure
6A). In agreement with this interpretation, the level of
packaged genomic RNA into newly formed viral particles
was decreased by 65 to 75% (Table 1B). Also in agreement
with the above interpretation is the observation that pro-
duction of high titer lentivectors necessitates expression of
the recombinant viral RNA at high levels in vector produc-
ing cells [36].
Despite the low level of incorporated Env (Figure 6), viri-
ons produced by cells overexpressing one SR protein
retained part of their infectivity on Hela P4 cells. This was
not unexpected since only a minimal amount of Env
appears to be required to drive infectivity in certain model
cell systems [37].
Conclusion
In summary, the data presented here show that elevated
concentrations of SR proteins in HIV-1 expressing cells
differentially affected viral RNA and protein expression,
resulting in a strong decrease of viral progeny made. Thus
one can speculate that the coordinated regulation of HIV-
1 splice site utilization by SR proteins is of critical impor-
tance to maintain high levels and balanced ratios of the
viral RNAs and hence of the viral proteins made in order
to direct optimal virus assembly and production. Thus,
HIV-1 probably needs to interact with the splicing
machinery. In accordance with this view, SC35 is up-regu-
lated and 9G8 down-regulated in HIV-1 infected cells
[38,39]. On a more general basis it has been found that SR
proteins influence expression and replication of other
viruses such as human papilloma virus type 16 [40] and
Adenovirus [41].
Materials and methods
Plasmids
Plasmids pXJ41-ASF, pXJ42-PR264 and pXJ42-9G8 [28]
that respectively encode ASF/SF2, SC35 and 9G8 in
eukaryotic cells were provided by J. Stevenin and R. Gat-
toni (IGBMC Strasbourg, France). The HIV-1 molecular
clone is pNL4.3 (GenBank #M19921) [27].
Cell cultures, transfections and infections
HeLa P4 (provided by P. Charneau) and 293T cells (pro-
vided by Genethon) were maintained in Dulbecco's mod-
ified Eagle's medium supplemented with 10 % fetal calf
serum, 2 mM glutamine and antibiotics (penicillin-strep-
tomycin; Invitrogen). One day before transfection, 3 × 106
293T cells were inoculated in 10-cm Petri dish (except for
experiments of Figure 1, see legend). One day later, cells
were transfected with 10 µg of proviral pNL4.3 and 4–10
µg of SR-expressing vector or of control plasmid pCLacZ
by the calcium phosphate precipitation technique accord-
ing to manufacturer instructions (Gibco). As observed by
immuno-staining and confocal microscopy, more than
70% of the cells were positively transfected. After 12 h, cell
culture supernatants were substituted by fresh culture
medium. Forty-eight hours after transfection, superna-
tants were harvested, clarified by filtration through 0.8
µm-pore size filters and ultracentrifuged through a 20 %
sucrose cushion. Pelleted viruses were resuspended in
TNE buffer (25 mM Tris HCl pH 7.5; 150 mM NaCl; 1 mM
EDTA). Virus production was monitored in cell culture
supernatants and in virus pellets with a CAp24 ELISA cap-
ture assay (kindly provided by Valérie Cheynet and Ber-
nard Mandrand, BioMérieux).
Viral titrations were performed by infection of HeLa P4
cells (1.5 × 105 cells per well of a 24-well plate) with puri-
fied viruses containing 1 ng of genomic RNA. After 24 h,
cells were fixed and incubated in the presence of X Gal
substrate at 37°C until blue color development was com-
plete. Viral titers were determined by counting the
number of blue cells in threee different wells.
RNA isolation, Northern blotting and RT-PCR
Transfected cells were harvested 48 h after transfection
and washed in phosphate-buffered saline (PBS). Two-
third of cells were resuspended in PBS and total cellular
RNA was extracted with TRIzol reagent as recommended
by the manufacturer (Invitrogen). Culture supernatants
were treated as indicated above and the level of CAp24
antigen measured by ELISA. Northern blotting of intracel-
lular viral RNAs was performed with 10 µg of total RNA
and slot-blot of virion-associated genomic RNA was per-
formed with 10 ng of CAp24 antigen. After transfer onto
a Hybond-N+ membrane (Amersham Pharmacia Bio-
tech), viral RNAs were probed with radiolabeled frag-
ments from Env for Northern blot and from Gag region
for slot-blot. All the mRNAs species were quantified by
Storm (Amersham).
The splicing products were analyzed by RT-PCR as previ-
ously described [10], except that the forward PCR primer
was Odp045 [2]. The PCR products were fractionated on
a 6 % acrylamide-7M urea electrophoresis gel and autora-
diographed. Individual HIV-1 mRNA species were named
according to the nomenclature of Purcell and Martin [2].
Immunoblotting
One-third of transfected cells were washed in PBS and
lysed in PBS containing 0.5 % Triton. After CAp24 ELISA
measurement in cell lysates and in virus pellets, samples
were added to 3X gel loading buffer (0.5 M Tris-HCl pH
6.8; 0.8 % SDS; 40 % glycerol; 5 % β -mercaptoethanol;
0.03 % bromophenol blue). For immunoblotting, sam-
ples containing equal amounts of CAp24 antigen were
loaded on a 10 % SDS-PAGE and fractionated proteins
were transferred onto a Hybond P membrane (AmershamRetrovirology 2005, 2:33 http://www.retrovirology.com/content/2/1/33
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Pharmacia Biotech). Viral proteins were probed with
monoclonal anti-CAp24 (BioMérieux), polyclonal anti-
Vpr (#3951, NIH USA), polyclonal anti-Nef (#331, NIH
USA) or monoclonal anti-TMgp41 (Ab 41A9; Hybridolab,
Pasteur) antibodies. The bound antibodies were detected
with peroxidase-conjugated anti-mouse IgG antibodies
and visualized by the SuperSignal West Pico Chemilumi-
nescent Substrate (Pierce).
Immunofluorescence staining and confocal microscopy 
imaging
Transfected 293 T cells were grown on poly-lysine coated
coverglass dishes and fixed 24 h post transfection in 3%
paraformaldehyde (diluted in Phosphate Buffer Saline –
PBS) for 20 min. The fixative was then removed and the
free aldehydes were quenched with 50 mM NH4Cl. Cells
were then permeabilized using 0.2 % Triton X-100 for 5
min and blocked in 1% BSA. The fixed cells were incu-
bated for one hour at room temperature with primary
antibodies: rabbit anti-MAp17 (NIH, USA), human anti-
HIV-1 gp120 Mab(b12) (NIH, USA), rabbit anti-His for
His-tagged 9G8 and ASF proteins, and mouse anti-HA1
for HA-tagged SC35 protein (Sigma). The corresponding
fluorescent Alexa® 488, 546 and 633-conjugated second-
ary antibodies were used at 0.5 µg/ml (Molecular probes).
Coverslips were washed three times with PBS and
mounted on microscope slides with Mowiol (Sigma).
Images were acquired on Axioplan 2 Zeiss CLSM 510 con-
focal microscope with Argon 488/458, HeNe 543, HeNe
633 lasers and plan apochromat 63 × 1.4 oil Ph3 objec-
tive, supplied with LSM 510 3.4 software.
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HIV-1, Human Immunodeficiency Virus type 1.
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